- Q4 2023 InflaRx NV Earnings Call TranscriptMar 21, 2024€1.43 (-9.51%)Earnings
- InflaRx NV Conference Call TranscriptJan 04, 2024
- InflaRx NV at HC Wainwright Investment Conference - New York TranscriptSep 11, 2023
- InflaRx NV Corporate Call TranscriptSep 11, 2023
- InflaRx NV PANAMO Ph3 Results Call TranscriptMar 31, 2022
- InflaRx NV Virtual R&D Event TranscriptFeb 03, 2022
- InflaRx NV at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Inflarx NV at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 10, 2021
- Inflarx NV Pyoderma Gangrenosum Cohort Three Top-Line Results Conference Call TranscriptOct 27, 2021
- Inflarx NV at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 23, 2021
- Inflarx NV at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Inflarx NV at JPMorgan Healthcare Conference TranscriptJan 16, 2020
- Q3 2019 Inflarx NV Earnings Call TranscriptNov 07, 2019€2.44 (+1.67%)Earnings
- InflaRx N.V. - Special Call TranscriptJul 19, 2019
InflaRx NV Corporate Call Transcript
Ladies and gentlemen, thank you for standing by. Welcome and thank you for joining InflaRx's conference call to discuss the results announced today from the Phase 1 study with INF904. (Conference Instructions)
I would now like to turn the call over to Dr. Niels Riedemann, CEO and Founder of InflaRx. Niels, please go ahead.
Yes. Thank you so much, Laurie. Good morning, everyone on this call. It's our great pleasure to present to you today the results from our single ascending dose Phase 1 study of our new oral C5a receptor inhibitor. Before going into it, I would like to direct your attention on the next two slides briefly to our corporate disclaimers. We will be making forward-looking statement and also, I have some comparison to published data from other drugs. So please take note of the disclaimer. And then I would like to come to the next slide, please. One more.
Thank you. So with me today are representing InflaRx. I have our C-suite team. It's my
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)